309 related articles for article (PubMed ID: 16255678)
1. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
Beher D; Graham SL
Expert Opin Investig Drugs; 2005 Nov; 14(11):1385-409. PubMed ID: 16255678
[TBL] [Abstract][Full Text] [Related]
2. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.
Barten DM; Meredith JE; Zaczek R; Houston JG; Albright CF
Drugs R D; 2006; 7(2):87-97. PubMed ID: 16542055
[TBL] [Abstract][Full Text] [Related]
3. Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease.
Churcher I; Beher D
Curr Pharm Des; 2005; 11(26):3363-82. PubMed ID: 16250842
[TBL] [Abstract][Full Text] [Related]
4. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Pollack SJ; Lewis H
Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
[TBL] [Abstract][Full Text] [Related]
5. γ-Secretase inhibitors and modulators for Alzheimer's disease.
Wolfe MS
J Neurochem; 2012 Jan; 120 Suppl 1(Suppl 1):89-98. PubMed ID: 22122056
[TBL] [Abstract][Full Text] [Related]
6. Gamma-secretase inhibition.
Beher D; Shearman MS
Biochem Soc Trans; 2002 Aug; 30(4):534-7. PubMed ID: 12196131
[TBL] [Abstract][Full Text] [Related]
7. The search for gamma-secretase and development of inhibitors.
Tsai JY; Wolfe MS; Xia W
Curr Med Chem; 2002 Jun; 9(11):1087-106. PubMed ID: 12052174
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying therapies in Alzheimer's disease: how far have we come?
Hüll M; Berger M; Heneka M
Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
[TBL] [Abstract][Full Text] [Related]
9. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
Harrison T; Churcher I; Beher D
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
[TBL] [Abstract][Full Text] [Related]
10. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity.
Shearman MS; Beher D; Clarke EE; Lewis HD; Harrison T; Hunt P; Nadin A; Smith AL; Stevenson G; Castro JL
Biochemistry; 2000 Aug; 39(30):8698-704. PubMed ID: 10913280
[TBL] [Abstract][Full Text] [Related]
11. Amyloid metabolism and secretases in Alzheimer's disease.
Xia W
Curr Neurol Neurosci Rep; 2001 Sep; 1(5):422-7. PubMed ID: 11898552
[TBL] [Abstract][Full Text] [Related]
12. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
Vassar R; Bennett BD; Babu-Khan S; Kahn S; Mendiaz EA; Denis P; Teplow DB; Ross S; Amarante P; Loeloff R; Luo Y; Fisher S; Fuller J; Edenson S; Lile J; Jarosinski MA; Biere AL; Curran E; Burgess T; Louis JC; Collins F; Treanor J; Rogers G; Citron M
Science; 1999 Oct; 286(5440):735-41. PubMed ID: 10531052
[TBL] [Abstract][Full Text] [Related]
13. Selective amyloid-beta lowering agents.
Wolfe MS
BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S4. PubMed ID: 19090992
[TBL] [Abstract][Full Text] [Related]
14. Gamma-secretase: a catalyst of Alzheimer disease and signal transduction.
Li YM
Mol Interv; 2001 Oct; 1(4):198-207. PubMed ID: 14993342
[TBL] [Abstract][Full Text] [Related]
15. Molecular rationale for the pharmacological treatment of Alzheimer's disease.
Zimmermann M; Gardoni F; Di Luca M
Drugs Aging; 2005; 22 Suppl 1():27-37. PubMed ID: 16506440
[TBL] [Abstract][Full Text] [Related]
16. Secretase as a target for Alzheimer's disease.
Wolfe MS
Curr Top Med Chem; 2002 Apr; 2(4):371-83. PubMed ID: 11966461
[TBL] [Abstract][Full Text] [Related]
17. Secretases as therapeutic targets for the treatment of Alzheimer's disease.
Dominguez DI; De Strooper B; Annaert W
Amyloid; 2001 Jun; 8(2):124-42. PubMed ID: 11409035
[TBL] [Abstract][Full Text] [Related]
18. The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.
Butini S; Brogi S; Novellino E; Campiani G; Ghosh AK; Brindisi M; Gemma S
Curr Top Med Chem; 2013; 13(15):1787-807. PubMed ID: 23931442
[TBL] [Abstract][Full Text] [Related]
19. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
20. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
